Kliniken & Institute ... Institute Pathologisches Institut... Abteilungen Neuropathologie Forschung Publikationen 2013 ...

Publikationen 2013

A complex secretory program orchestrated by the inflammasome controls paracrine senescence.
Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J.
Nat Cell Biol. 2013 15(8):978-990

Targeting the BRAF V600E Mutation in Multiple Myeloma.
Andrulis A, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho A, Goldschmidt H, Neben K, Raab M.
Cancer Discovery. 2013 3(8):862-869

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Baumgarten P, Harter PN, Tonjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kogel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zornig M, Mittelbronn M. Neuropathology and applied neurobiology. 2013

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas.
Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, Radlwimmer B, Hojfeldt JW, Truffaux N, Castel D, Schubert S, Ryzhova M, Seker-Cin H, Gronych J, Johann PD, Stark S, Meyer J, Milde T, Schuhmann M, Ebinger M, Monoranu CM, Ponnuswami A, Chen S, Jones C, Witt O, Collins VP, von Deimling A, Jabado N, Puget S, Grill J, Helin K, Korshunov A, Lichter P, Monje M, Plass C, Cho YJ, Pfister SM.
Cancer Cell. 2013 24(5):660-672

Lack of BRAF V600E protein expression in primary central nervous system lymphoma.
Berghoff AS, Capper D, Preusser M.
Appl Immunohistochem Mol Morphol. 2013 21(4):351-353

Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma.
Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, Dewire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ.
Clin Cancer Res. 2013 19(24):6716-6729

Detection of the V600E BRAF mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H, Fischer A, Pham D, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.
Hum Pathol. 2013 44(3):329-335

Immunohistochemical analysis of BRAFV600E-expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Busam K, Hedvat C, Pulitzer M, von Deimling A, Jungbluth A. American Journal of Surgical Pathology. 2013 37(3):413-420

Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes.
Busam K, Sung J, Wiesner T, von Deimling A, Jungbluth A.
American Journal of Surgical Pathology. 2013 37(2):193-199

BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D, Voigt A, Bozukova G, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.
Int J Cancer. 2013 133(7):1624-1630

Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution.
Colin C, Padovani L, Chappe C, Mercurio S, Scavarda D, Loundou A, Frassineti F, Andre N, Bouvier C, Korshunov A, Lena G, Figarella-Branger D.
Neuropath Appl Neurobiol. 2013 39(6):693-705

Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
Colomba E, Hélias-Rodzewicz Z, von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté J-F, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile J-F.
Journal of Molecular Diagnostics. 2013 7(11):e47595

Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma.
Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A.
PLoS One. 2013 8(3):e57924

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S, Hullein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Frohling S, von Kalle C, Glimm H, Ho AD, Zenz T.
J Clin Oncol. 2013 31(19):e300-303

Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, Kool M, Jones DT, Unterberger A, Morrissy AS, Shih D, Peacock J, Ramaswamy V, Rolider A, Wang X, Witt H, Hielscher T, Hawkins C, Vibhakar R, Croul S, Rutka JT, Weiss WA, Jones SJ, Eberhart CG, Marra MA, Pfister SM, Taylor MD.
Acta Neuropathol. 2013 125(3):373-384

Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C, Mittelbronn M.
J Neuropathol Exp Neurol. 2013 72(10):933-941

Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model.
Harter PN, Dutzmann S, Drott U, Zachskorn C, Hattingen E, Capper D, Gessler F, Senft C, Seifert V, Plate KH, Kogel D, Mittelbronn M.
Neuropathology. 2013 33(5):515-525

Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn J, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M.
Clinical Cancer Research. 2013 19(18):5146-5157

Bed isolation in experimental flap studies in rats: a dispensable procedure.
Heimer S, Schaefer A, Mueller W, Lass U, Gebhard MM, Germann G, Leimer U, Kollensperger E, Reichenberger MA.
Ann Plast Surg. 2013 70(3):354-359

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G.
Neuro Oncol. 2013

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
Ilie M, Long E, Hofman V, Dadone B, Marquette C, Mouroux J, Vignaud J, Begueret H, Merlio J, Capper D, von Deimling A, Emile J-F, Hofman P.
Ann Oncol. 2013 24(3):742-748

Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer.
Jager N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, Richter J, Hummel M, Mack SC, Taylor MD, Witt H, Swartman B, Schulte-Bockholt D, Sultan M, Yaspo ML, Lehrach H, Hutter B, Brors B, Wolf S, Plass C, Siebert R, Trumpp A, Rippe K, Lehmann I, Lichter P, Pfister SM, Eils R.
Cell. 2013

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Jones D, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz H-J, Zichner T, Lambert S, Ryzhova M, Quang D, Fontebasso A, Stütz A, Hutter S, Zuckermann M, Sturm D, Gronych J, B L, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott P, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber U, Zapatka M, Raeder B, Schlesner M, Worth C, Bartholomae C, von Kalle C, Imbusch C, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik A, Ebinger M, Schuhmann M, Cho Y-J, Pomeroy S, von Deimling A, Witt O, Taylor M, Wolf S, Karajannis M, Eberhart C, Scheurlen W, Hasselblatt M, Ligon K, Kieran M, Korbel J, Yaspo M-L, Brors B, Felsberg J, Reifenberger G, Collins V, Jabado N, Eils R, Lichter P, Pfister S, Project38 obotIPT.
Nature Genetics. 2013 45(8):927-932

A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.
Klink B, Miletic H, Stieber D, Huszthy P, Valenzuela J, Balss J, Wang J, Schubert M, Sakariassen P, Sundstrøm T, Torsvik A, Aarhus M, Mahesparan R, von Deimling A, Kaderali L, Niclou S, Schröck E, Bjerkvig R, JM. N.
PLoS one. 2013 8(3):e59773

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A.
Acta Neuropathol. 2013 126(6):907-915

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.
Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D.
Acta Neuropathologica. 2013 125(6):891-900

Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, Gupta T, Krishnatry R, Kannan S, Kurkure P, Deopujari C, Shetty P, Biyani N, Korshunov A, Pfister SM, Northcott PA, Shirsat NV.
Neuro Oncol. 2013 15(12):1644-1651

Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma.
Lambert SR, Witt H, Hovestadt V, Zucknick M, Kool M, Pearson DM, Korshunov A, Ryzhova M, Ichimura K, Jabado N, Fontebasso AM, Lichter P, Pfister SM, Collins VP, Jones DT.
Acta Neuropathologica. 2013

Protein kinase Cβ as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis.
Lanz T, Becker S, Osswald M, Bittner S, Schuhmann M, Opitz C, Gaikwad S, Wiestler B, Litzenburger U, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth S, Wick W, Platten M.
PNAS. 2013 110(36):14735-14740

Chromogenic In Situ Hybridization is a Reliable Alternative to Fluorescence In Situ Hybridization for Diagnostic Testing of 1p and 19q loss in paraffin embedded gliomas.
Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M, Mueller W.
Brain Pathology. 2013 23(3):311-318

The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH.
Cell. 2013 153(5):1064-1079

Highly prevalent TERT promoter mutations in bladder cancer and gliobastoma.
Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M.
Cell Cycle. 2013 12(10):1637-1638

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long G, Wilmott J, Capper D, Preusser M, Zhang Y, Thompson J, Kefford R, von Deimling A, Scolyer R.
American Journal of Surgical Pathology. 2013 37(1):61-65

Emerging insights into the ependymoma epigenome.
Mack SC, Witt H, Wang X, Milde T, Yao Y, Bertrand KC, Korshunov A, Pfister SM, Taylor MD.
Brain Pathology. 2013 23(2):206-209

Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz I, Antonetti P, Pusch S, Capper D, Balss J, Voigt S, Weissert S, Mukrowsky A, Frank J, Senft C, Seifert V, von Deimling A, Kögel D.
Apoptosis. 2013 18(11):1416-1425

Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
Navis A, Niclou S, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers R, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden C, Wesseling P, Leenders W.
Acta Neuropathologica Communications. 2013 1(18):

Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
Ochs K, Sahm F, Opitz CA, Lanz TV, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M.
J Neuroimmunol. 2013 265(1-2):106-116

No Evidence for BRAF-V600E Mutations in Gastro-Esophageal Tumors: Results from a high-throughput Analysis of 534 Cases using a mutation-specific Antibody.
Preusser M, Berghoff A, Capper D, von Deimling A, Maroske F, Brodowicz T, Hejna M, Birner P, Schoppmann S.
Applied Immunohistochemistry & Molecular Morphology. 2013 21(5):426-430

Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies Preusser M, Berghoff A, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi C, Hejna M, Capper D, von Deimling A, Schoppmann S, Birner P.
Anticancer Research. 2013 33(3):1065-1071

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
Preusser M, Berghoff A, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Woehrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann S, Zielinski C, Streubel B, Birner P.
Lung Cancer. 2013 80(3):278-283

Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M, Capper D, Berghoff A, Horvat R, Wrba F, Schindl M, Schoppmann S, von Deimling A, Birner P.
Applied Immunohistochemistry & Molecular Morphology. 2013 21(2):162-167

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schuller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, Pomeroy SL, Dunn S, Triscott J, Jabado N, Fontebasso A, Jones DT, Kool M, Karajannis MA, Gardner SL, Zagzag D, Nunes S, Pimentel J, Mora J, Lipp E, Walter AW, Ryzhova M, Zheludkova O, Kumirova E, Alshami J, Croul SE, Rutka JT, Hawkins C, Tabori U, Codispoti KE, Packer RJ, Pfister SM, Korshunov A, Taylor MD.
Lancet Oncol. 2013 14(12):1200-1207

Somatostatin receptor subtype 2 (sst(2)) is a potential prognostic marker and a therapeutic target in medulloblastoma. Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerss J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor MD, Pietsch T, Rutkowski S, Korshunov A, Monoranu CM, Fruhwald MC. Childs Nerv Syst. 2013 29(8):1253-1262

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, Jung S, Saad AG, Liau LM, Albrecht S, Zollo M, Cooper MK, Thompson RC, Delattre OO, Bourdeaut F, Doz FF, Garami M, Hauser P, Carlotti CG, Van Meter TE, Massimi L, Fults D, Pomeroy SL, Kumabe T, Ra YS, Leonard JR, Elbabaa SK, Mora J, Rubin JB, Cho YJ, McLendon RE, Bigner DD, Eberhart CG, Fouladi M, Wechsler-Reya RJ, Faria CC, Croul SE, Huang A, Bouffet E, Hawkins CE, Dirks PB, Weiss WA, Schuller U, Pollack IF, Rutkowski S, Meyronet D, Jouvet A, Fevre-Montange M, Jabado N, Perek-Polnik M, Grajkowska WA, Kim SK, Rutka JT, Malkin D, Tabori U, Pfister SM, Korshunov A, von Deimling A, Taylor MD.
Acta Neuropathol. 2013 126(6):917-929

Sensitivity of Malignant Peripheral Nerve Sheath Tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by Curcumin through induction of ROS. Reuss D, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V, von Deimling A. PLoS One. 2013 8(2):e57253

Functional MHC class II is up-regulated in Neurofibromin deficient Schwann cells Reuss D, Mucha J, Holtkamp N, Müller U, Berlien H-P, Mautner V-F, Ehemann V, Platten M, Scheffzek K, von Deimling A.
Journal of Investigative Dermatology. 2013 133(5):1372-1375
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss D, Piro R, Jones D, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jäger N, Santarius T, Tarpey P, Stephens P, Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins V, König R, Wiestler O, Pfister S, von Deimling A.
Acta Neuropathologica. 2013 125(3):351-358

Nbn and Atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye.
Rodrigues P, Grigaravicius P, Remus M, Cavalheiro G, Gomes A, Martins M, Frappart L, Reuss D, McKinnon P, von Deimling A, Martins R, Frappart P-O.
PLoS One. 2013 8(7):e69209

AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, Bohmer K, Lass U, Gock T, Kalis K, Meyer J, Habel A, Brehmer S, Mittelbronn M, Jones DT, Schittenhelm J, Urbschat S, Ketter R, Heim S, Mawrin C, Hainfellner JA, Berghoff AS, Preusser M, Becker A, Herold-Mende C, Unterberg A, Hartmann C, Kickingereder P, Collins VP, Pfister SM, von Deimling A.
Acta Neuropathologica. 2013 126(5):757-762

The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Sahm F, Opitz C, Ahrendt T, Radlwimmer B, Bode H, von Deimling A, Wick W, Platten M.
Cancer Research. 2013 73(11):3225-3234

Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.
Schweizer L, Koelsche C, Sahm F, Piro R, Capper D, Reuss D, Pusch S, Habel A, Meyer J, Göck T, Jones D, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, König R, Wiestler O, Pfister S, von Deimling A.
Acta Neuropathologica. 2013 125(5):651-658

VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation.
Sperveslage J, Gierke M, Capper D, Honegger J, Sipos B, Beschorner R, Schittenhelm J.
Acta Neuropathologica. 2013 125(6):911-912

BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome.
Toon C, Walsh M, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters R, Clendenning M, Rosty C, Young J, A. W, Hopper J, Crook A, von Deimling A, Jenkins M, Buchanan D, Gill A.
American Journal of Surgical Pathology. 2013 37(10):1592-1602

Interlaboratory comparison of IDH mutation detection.
van den Bent M, Hartmann C, Preusser M, Ströbel T, Dubbink H, Kros J, von Deimling A, Sanson M, Halling K, Diefes K, Aldape K, Giannini C.
Journal of Neuro-Oncology. 2013 112(2):173-178

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.
Weiler M, Pfenning P-N, A-L. T, Blaes J, Jestaedt L, Gronych J, Dittmann L, Berger B, Jugold M, Kosch M, Combs S, von Deimling A, Weller M, Bendszus M, Platten M, Wick W.
Oncogene. 2013 32(9):1099-1109

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
Neurology. 2013 81(17):1515-1521

Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Wick W, Steinbach J, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs S.
Neuro-Oncology. 2013 15(10):1405-1412

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister S, Platten M, Weller M, Wick W.
Acta Neuropathol. 2013 126(3):443-451

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Muller W, Plass C, Weller M, Wick W.
Neuro Oncol. 2013 15(8):1017-1026

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
Wilmott J, Menzies A, Haydu L, Capper D, Preusser M, Zhang Y, Thompson J, Kefford R, von Deimling A, Scolyer R, Long G.
British Journal of Cancer. 2013 108(4):924-931

BRAF mutations in melanocytic nevi are fully clonal, consistent with an initiating role of BRAF in the formation of melanocytic neoplasia.
Yeh I, von Deimling A, Bastian B.
Journal of the National Cancer Institute. 2013 105(12):917-919

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren AO, Jones DT, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schuller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford SC, Korshunov A, Pfister S, Taylor MD, Tabori U.
J Clin Oncol. 2013 31(23):2927-2935

BRAF V600E expression and distribution in desmoplastic infantile astrocytoma / ganglioglioma.
Koelsche C, Sahm F, Paulus W, Mittelbronn M, Giangaspero F, Antonelli M, Meyer J, Lasitschka F, von Deimling A, Reuss D.
Neuropathol Appl Neurobiol. 2013

BRAF-Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and CD34 Expression.
Koelsche C, Sahm F, Wöhrer A, Jeibmann A, Schittenhelm J, Kohlhof P, Preusser M, Romeike B, Dohmen-Scheufler H, Hartmann C, Mittelbronn M, Becker A, von Deimling A, Capper D.